Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

about

Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study

P2860

Q42654060-4B149F27-4EC1-4659-A8AB-3C733285A526 Q59137107-A6D0E52E-8C70-4793-B088-DA0CDEB3C5A0

P2860

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Item

http://www.wikidata.org/entity/Q38989517

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Individualized, patient-center ...... t of type 2 diabetes mellitus.

@en

type

Item

label

Individualized, patient-center ...... t of type 2 diabetes mellitus.

@en

prefLabel

Individualized, patient-center ...... t of type 2 diabetes mellitus.

@en

P1476

Individualized, patient-center ...... t of type 2 diabetes mellitus.

@en

P2093

Denis Raccah

http://www.w3.org/2001/XMLSchema#string

Louis Monnier

http://www.w3.org/2001/XMLSchema#string

P2860

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness

Glycemic Variability: How Do We Measure It and Why Is It Important?

The L-Cell in Nutritional Sensing and the Regulation of Appetite

GLP-1 receptor agonists: a review of head-to-head clinical studies

Cognitive dysfunction and diabetes mellitus

Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis.

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women.

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

P304

311-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1251579

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Markolf Hanefeld

P577

2016-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27776453

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

about

P2860

P2860

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921